Bavarian Nordic Announces Interim Results for the First Three Months of 2019

NEXT STORY
Centauri’s AlphamerTM Platform highlighted at 4th Annual Advances in Immuno-Oncology Congress
PREV STORY
Novartis phase II data for new inhaled combination treatment (QVM149) demonstrates significant improvements over current standard-of-care inhaled treatment
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Chiasma Reports Third Quarter 2017 Results

WALTHAM, Mass., Nov. 09, 2017 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ:CHMA), a clinical-stage biopharmaceutical ...

author_avatar
NASDAQ Market News

SANUWAVE Announces 24-Week Data From Its Pivotal Trials Investigating the Use of dermaPACE for the Treatment of Diabetic Foot Ulcers

ALPHARETTA, Ga., March 24, 2016 (GLOBE NEWSWIRE) -- SANUWAVE Health, Inc. (OTCBB:SNWV) (www.sanuwave.com), today ...

author_avatar
NASDAQ Market News

Merit Medical Signs Purchase Agreement with BD for Divestment Assets

SOUTH JORDAN, Utah, Nov. 16, 2017 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), ...

author_avatar
NASDAQ Market News